Home > Insider Trading > Filing (0001447362-21-000010)

Filing Details

Accession Number:: 0001447362-21-000010
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-13 16:08:00
Reporting Period:: 2021-01-11

Accepted Time:: 2021-01-13 16:08:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1447362	Castle Biosciences Inc	CSTL	Services-Medical Laboratories (8071)	770701774

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1782815	Frank Stokes	C/O Castle Biosciences, Inc. 820 S. Friendswood Drive, Suite 201 Friendswood TX 77546	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-11	7,500	$2.39	11,386	No	4	M	Direct
Common Stock	Disposition	2021-01-11	1,300	$77.35	10,086	No	4	S	Direct
Common Stock	Disposition	2021-01-11	6,000	$78.17	4,086	No	4	S	Direct
Common Stock	Disposition	2021-01-11	200	$79.26	3,886	No	4	S	Direct
Common Stock	Acquisiton	2021-01-12	7,500	$2.39	11,386	No	4	M	Direct
Common Stock	Disposition	2021-01-12	1,500	$77.02	9,886	No	4	S	Direct
Common Stock	Disposition	2021-01-12	4,900	$78.29	4,986	No	4	S	Direct
Common Stock	Disposition	2021-01-12	1,100	$78.98	3,886	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2021-01-11	7,500	$0.00	7,500	$2.39
Common Stock	Stock option (right to buy)	Disposition	2021-01-12	7,500	$0.00	7,500	$2.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,637		2028-05-09	No	4	M	Direct
40,137		2028-05-09	No	4	M	Direct

Footnotes

These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020.
This transaction was executed in multiple trades at prices ranging from $76.950 to $77.790, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $78.000 to $78.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $79.255 to $79.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $76.625 to $77.310, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $77.770 to $78.730, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $78.850 to $79.155, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.